Showing results (41-50 of 132) with videos related to

Sort By:
Pageof 14
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
AIDS Patient Care and Stds|March 13, 2012
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE studyCheryl McDonald, Jonathan Uy, Wenhua Hu, et al.
AIDS (London, England)|May 29, 2004
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendationsBonaventura Clotet, François Raffi, David Cooper, et al.
AIDS (London, England)|July 1, 2011
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished dataMario Cruciani, Veronica Zanichelli, Giovanni Serpelloni, et al.
Plos One|July 9, 2016
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyJosep M Llibre, François Raffi, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2017
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledgeEmilie R Elliot, Alieu Amara, Nicole Pagani, et al.
Plos One|May 20, 2016
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyJosep M Llibre, François Raffi, Graeme Moyle, et al.
The Journal of Clinical Endocrinology and Metabolism|June 18, 2010
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataJulian Falutz, Jean-Claude Mamputu, Diane Potvin, et al.
HIV Research & Clinical Practice|September 23, 2021
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patientsMargherita Bracchi, Nicole Pagani, Alessia Dalla Pria, et al.
Pageof 14